Trial Profile
A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (sorafenib) versus standard treatment with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2005
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Interferon alpha-2a
- Indications Renal cancer
- Focus Therapeutic Use
- 27 Oct 2005 New trial record.